We use third-party cookies to provide support. By continuing to browse this website,
you accept our privacy policy.
Arcellx Inc
1 watching
Current Price
$0
$0.34
(1.04%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Market Capitalization
1,429.39M
52-Week High
35.16
52-Week Low
6.035
Average Volume
0.06M
Dividend Yield
--
P/E Ratio
--
Market Capitalization1,429.39M52-Week High35.1652-Week Low6.035Average Volume0.06MDividend Yield--P/E Ratio--What does the Arcellx Inc do?
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company s lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Read More
How much money does Arcellx Inc make?
News & Events about Arcellx Inc.
Zolmax
2days ago
Arcellx, Inc. (NASDAQ:ACLX Get Rating) saw a significant increase in short interest during the month of January. As of January 15th, there was short interest totalling 2,710,000 shares, an increase of 13.4% from the December 31st total of 2,390,000 shares. Currently, 10.6% of the shares of the ...
Ticker Report
30days ago
Arcellx, Inc. (NASDAQ:ACLX Get Rating) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 2,460,000 shares, a drop of 13.7% from the November 30th total of 2,850,000 shares. Approximately 11.1% of the ...
Zolmax
30days ago
Arcellx, Inc. (NASDAQ:ACLX Get Rating) was the target of a significant drop in short interest in the month of December. As of December 15th, there was short interest totalling 2,460,000 shares, a drop of 13.7% from the November 30th total of 2,850,000 shares. Approximately 11.1% of the shares of the...
Business Wire
1month ago
Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced a global strategic collaboration to co-develop and co-commercialize Arcellxs lead late-stage product candidate, CART-ddBCMA, for the treatment of patients with relapsed or refractory multiple myeloma. Multiple...
PR Newswire
1month ago
Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in Patients with Relapsed or Refractory Multiple Myeloma and Additional Pipeline Progress Arcellx Announces Continued Robust Long-Term Responses from its CART-ddBCMA Phase 1 Expansion Trial in...
Frequently Asked Questions
Frequently Asked Questions
What is Arcellx Inc share price today?
Can Indians buy Arcellx Inc shares?
How can I buy Arcellx Inc shares from India?
Can Fractional shares of Arcellx Inc be purchased?
What are the documents required to start investing in Arcellx Inc stocks?
What is today’s traded volume of Arcellx Inc?
What is today’s market capitalisation of Arcellx Inc?
What is the 52-Week High and Low Range of Arcellx Inc?
What percentage is Arcellx Inc down from its 52-Week High?
What percentage is Arcellx Inc up from its 52-Week Low?
Current Price
$0
$0.34
(1.04%)
1 Week Returns
3 Months Returns
1 Year Returns
Get Started with as little as $1.00
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.
Sign up and dive into a whole new world of investing.
Join over 280,000 who have signed up and are using Stockal successfully already.